Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast start, according to HSBC.

Brandon W. Shirley is senior counsel, Madison Hartman Harada is a senior associate and Thomas M. Abrams is an associate at Krieg DeVault LLP. Opinions expressed are those of the authors.

Key companies developing therapies for Necrotizing Enterocolitis are - Abbott, Astellas Pharma Inc., Bayer HealthCare AG, Becton, Dickinson, and Company (BD), Bristol-Myers Squibb Company, Daiichi ...

AstraZeneca and its partner Daiichi Sankyo have obtained the Food and Drug Administration’s green light for Datroway to treat an advanced form of non-small cell lung cancer in adults who had ...